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Truncated m2 and m3 muscarinic receptors (referred to as m2- and m3-trunc), containing transmembrane domains I-V and the N-terminal portion 
of the third cytoplasmic loop, were co-expressed in COS-7 cells with the corresponding C-terminal receptor fragments (referred to as m2- and 
m3-tail; containing transmembrane domains VI and VII). Expression of any of these four polypeptides alone did not result in any detectable 
[“H]N-methylscopolamine ([‘HINMS) binding activity. However, specific [‘H]NMS binding sites were observed after co-expression of m2-trunc with 
m2-tail and m3-trunc with m3-tail. These sites displayed ligand binding properties imilar to those of the two wild-type receptors. The ‘reconstituted’ 
m3-trunc/m3-tail receptor was also able to stimulate agonist-dependent phosphatidyl inositol hydrolysis in a fashion similar to the wild-type m3 
receptor, whereas all other polypeptide combinations were inactive. These data suggest hat muscarinic receptors are assembled in a fashion 
analogous to two-subunit receptors. 
G protein-coupled receptor; Muscarinic receptor; Phosphatidyl mositol hydrolysis; Protein folding; Truncated receptor 
1. INTRODUCTION 
The muscarinic acetylcholine receptors (ml-m5) are 
members of the family of plasma membrane receptors 
that transduce their intracellular signals via coupling to 
guanine nucleotide-binding regulatory proteins (G pro- 
teins) [l-3]. Like all other G protein-coupled receptors, 
the muscarinic receptors are predicted to be composed 
of seven hydrophobic (a-helical) membrane-spanning 
domains connected by alternating cytoplasmic and ex- 
tracellular loops, a glycosylated extracellular N-termi- 
nal domain and an intracellular C-terminal region. The 
seven transmembrane domains (TM I-VII) are pre- 
dicted to enclose a highly conserved cavity in which the 
binding of muscarinic ligands is thought to occur [3-71. 
In contrast, the selectivity of G protein coupling dis- 
played by the individual receptor subtypes appears to 
be primarily dependent on the membrane-proximal por- 
tions of the third cytoplasmic loop (i3) [8-121. 
Little is known about the molecular mechanisms con- 
trolling the folding and assembly of muscarinic and 
other G protein-linked receptors. Interestingly, bio- 
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taining the entire coding sequences of the human m2 and the rat m3 
muscarinic receptors (151, respectively, were used to construct various 
fragmented muscarinic receptor genes coding for m2-trunc, m3-trunc, 
m2-tail, and m3-tail (Fig. 1). Expression plasmids coding for these four 
polypeptides (pcDm2-trunc, pcDm3-trunc, pcDm2-tail, and pcDm3- 
tail) were created as described in Fig. 2. 
chemical studies have shown that bacteriorhodopsin (a 
structurally related transmembrane protein which func- 
tions as a light-driven proton pump) consists of several 
‘autonomous folding domains’ which, following their 
independent insertion into the lipid bilayer, can interact 
with each other to form a functional transmembrane 
protein (for reviews, see [13,14]). 
To test the hypothesis that the biosynthetic assembly 
of muscarinic receptors is based on a similar mecha- 
nism, we prepared a series of fragmented m2 and m3 
muscarinic receptor genes encoding the polypeptides 
shown in Fig. 1. mZtrunc and m3-trunc (containing 
TM I-V) represent muscarinic receptors which have 
been truncated within the i3 domain, whereas m2-tail 
and m3-tail consist of the C-terminal half of i3 and the 
remaining C-terminal receptor sequences (including 
TM VI and VII). The different polypeptides were ex- 
pressed in COS-7 cells, either alone or in various combi- 
nations, and studied for their ability to bind muscarinic 
ligands and to stimulate phosphatidyl inositol (PI) hy- 
drolysis. 
2. MATERIALS AND METHODS 
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Fig. 1. Amino acid sequence and predicted transmembrane disposition of fragmented human m2 and rat m3 muscarinic receptors. Expression 
plasmids coding for the various polypeptides were prepared as described in section 2. The different receptor fragments are composed as follows 
(amino acid numbers of the wild-type m2 or m3 receptor sequences are given m parentheses): m2-trunc (I-283) m2-tail(281-466). m3-trunc (1-272). 
and m3-tail(388-589). Only the membrane-proximal portions of the N- and C-termini of the various polypeptides are shown (dashed hnes indicate 
receptor sequences not shown in this scheme). The intracellular C-termini of m2- and m3-trunc consist of 56 and 21 ammo acids, respectively. The 
intracellular N-termini of m2- and m3-tail are composed of 109 and 105 amino acids, respectively. The methionine codons at the N-termmi of m2- 









Antagonist bmding properties of muscarinic receptor fragments co-expressed in COS-7 cells 
B,,, (fmol/mg) [3H]NMS 4-DAMP 
Kn (PM) %i K, (nM) nH 
1.215 f 189 62f 7 0.99 f 0.18 3.3 + 0.3 1.02 f 0.04 
475f 16 79? 10 0.92 f 0.09 3.7 + 0.2 0.98 f 0.04 
389 f 25 34+ 2 1.09 f 0.12 1.0 + 0.05 0.96 f 0.04 
1,141 f 51 29f 2 1.05 f 0.10 0.40 + 0.03 0.99 f 0.05 
114f 17 232 2 1.00 f 0.11 0.40 + 0.02 0.99 f 0.05 
no specific [‘HINMS binding detectable 
[‘H]NMS affinity constants (Ko) were determined in direct binding assays. Inhibition constants (K,) for 4-DAMP were obtained in competition 
binding experiments as described in section 2 (n,, = Hill coefficient). B,,, values represent maximal number of bindmg sites, expressed as fmol/mg 
of membrane protein. Data are presented as means f S.E.M. of two or three Independent experiments, each performed in duplicate. 
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________--_____________________-------__--_-__---------------______________----- 
Plasmid Fragments used Linker sequence 
for ligation 
_----___--______-______----_-----_---~~~------_-----~~~____------___-------_____ 
pcDm2-trunc Sst I - Sst I (5.3 kb) (Self-ligation creates an in-frame stop codon after Ser283) 
pcDm3-trunc Bstx I - Nhe I (6.1 kb) 
pcDm2-tail Sst I - Hind Ill (4.5 kb) 
Hind Ill - Pst I (0.5 kb) 
5’ CTGGCTGGCCTACAGGCTCTGGGACATGAG 3’ 
3’ TCTCGACCGACCGGATGTCCGAGACCCTGTACTCGATC 5’ 
Bstx I Nhe I 
ML?! 
5’ GATTAGAGAACGCAAAATGGAGAGCT 3’ 
3’ ACGTCTAATCTCTTGCGTTTTACCTC 5’ 
Pst I Sst I 
m 
pcDm3-tail Pst I - Cfr 10 (4.1 kb) 5’ GATCCCTATGTCAGAGAGTCACAATGCTGCA 3’ 
Cfr 10 - BamH I (1.4 kb) 3’ GGATACAGTCTCTCAGTGTTACG 5’ 
BamH I Pst I 
----- --__ ____--_----_----------- 
Fig. 2. Construction of expression plasmids encoding muscarinic receptor fragments. Hm2pcD and Rm3pcD, two mammalian expression plasmids 
containing the entire coding sequences of the human m2 and the rat m3 muscarinic receptors [15], respectively, were used to construct various 
fragmented muscarinic receptor genes. DNA linkers were prepared on an Applied Biosystems 3280B DNA Synthesizer. Single-stranded oligonu- 
cleotides were purified by polyacrylamide gel electrophoresis, annealed (resulting m the creation of cohesive ends), and then ligated with the 
indicated restriction fragments prepared from either Hm2pcD (pcDm2-tail) or Rm3pcD (pcDm3-trunc and pcDm3-tail) (see section 2). 
2.1. I. pcDm2-trunc 
A 5.3 kb &t&fragment was removed from Hm2pcD and subjected 
to self-ligation, resulting in the creation of a stop codon after amino 
acid codon 283 of the human m2 sequence. 
2.1.2. pcDm3-tnmc 
A 0.70 kb BstXI-NheI fragment was removed from Rm3pcD and 
replaced with a synthetic linker sequence containing an in-frame stop 
codon after amino acid codon 272 of the rat m3 sequence. 
2.1.3. pcDm2-tail and pcDm3-tail 
To construct pcDm2-tail, a 0.90 kb PstI-SstI restriction fragment 
was removed from Hm2pcD and replaced with a synthetic DNA linker 
sequence containing an in-frame translation initiation codon (ATG) 
and a short stretch of adjacent 5’ untranslated sequence present in 
Hm2pcD. The resulting plasmid encodes the C-terminal 185 amino 
acids (amino acids 281-466) of the human m2 receptor. For the crea- 
tion of pcDm3-tail, a 1.3 kb BumHI-PstI restriction fragment was cut 
out from Rm3pcD and replaced with a synthetic DNA linker sequence 
containing an in-frame translation initiation codon (ATG) and a short 
stretch of adjacent 5’ untranslated sequence of Rm3pcD. The resulting 
construct codes for the C-terminal 202 amino acids (amino acids 
388-589) of the rat m3 muscarinic receptor. 
The identity of all constructs was confirmed by dideoxy sequencing 
[16] of the regions derived from the synthetic oligonucleotides and by 
restriction endonuclease analysis. 
2.2. Construction of expression plasmids containing two transcriptional 
units 
To allow the efficient co-expression of the various muscarinic recep- 
tor fragments, plasmids with two transcriptional units were con- 
structed. The SalI-Tthl 1 II fragments containing the SV40 early re- 
gion promoter, the m2-tail or m3-tail coding sequence, and the seg- 
ment carrying the SV40 late region polyadenylation signal were re- 
moved from pcDm2-tail or pcDm3-tail, respectively, blunt-ended, and 
cloned into the blunt-ended SalI site present in pcDm2-trunc or 
pcDm3-trunc. Restriction endonuclease analysis verified that both 
transcriptional units were present in the same orientation. All possible 
pcDtruncltai1 combinations were constructed: pcDm2-trunc/m2-tail, 
pcDm2-trunc/m3-tail, pcDm3-trunc/m3-tail, and pcDm3-trunc/m2- 
tail. The structural features of the pcD vector system used to construct 
the various expression plasmids have been described by Okayama and 
Berg [17]. 
2.3. Transfections and membrane preparation 
Unless otherwise indicated, COS-7 cells were transfected with 2Opg 
of plasmid DNA in IOO-mm plates by using a calcium phosphate 
precipitation method [18]. Cells were harvested 72 h after transfec- 
tions, and membrane homogenates were prepared as described previ- 
ously [19]. Protein concentrations were determined according to the 
method of Bradford [20] using a Bio-Rad protein assay kit. 
2.4. Ligands 
[‘H]N-Methylscopolamine ([3H]NMS; 78.9 Ci/mmol) was pur- 
chased from DuPont-New England Nuclear. 4-Diphenylacetoxy-N- 
methylpiperidine methiodide (CDAMP) was obtained from Research 
Biochemicals Inc. Acetylcholine, carbachol and atropine were from 
Sigma. 
2.5. Ligand binding studies 
Radioligand binding studies were carried out with membrane ho- 
mogenates essentially as described [19]. In the competition binding 
experiments, a [‘HINMS concentration of 200 pM was used. Non- 
specific binding was determined in the presence of 1 PM atropine. 
Data were analyzed by a non-linear least-squares curve fitting proce- 
dure as described [19]. 
2.6. PI assays 
Transfected COS-7 cells were incubated with 3 @i/ml myo- 
[‘H]inositol(23 Wmmol, American Radiolabeled Chemicals Inc.) for 
48 h. Carbachol-induced increases in mtracellular inositol mono- 
phosphate (IP,) levels were determined as described [21]. 
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3. RESULTS 
For co-expression experiments, expression plasmids 
containing two transcriptional units (see section 2) were 
used. The ligand binding and functional properties of 
the expressed polypeptides (polypeptide complexes; Fig. 
1) were determined and compared with those of the 
wild-type m2 and m3 muscarinic receptors. 
m2 and m3 receptors, respectively, and thus retained the 
same spectrum of agonist binding selectivity displayed 
by the wild-type receptors (Table II). The chimeric m2- 
trunc/m3-tail receptor complex displayed agonist bind- 
ing affinities that were intermediate between those 
found for the two wild-type receptors. 
3.3. Stimulation of PI hydrolysis 
3.1. Antagonist binding studies 
None of the four muscarinic receptor fragments (Fig. 
1) showed detectable [3H]NMS binding activity when 
expressed alone in COS-7 cells. In contrast, a consider- 
able number of specific [3H]NMS binding sites was ob- 
served after co-expression of m2-trunc with m2-tail 
(m2- trunc/m2-tail) and of m3-trunc with m3-tail (m3- 
trunc/m3-tail) (Table I). The calculated [3H]NMS KD 
values were similar to those found for the wild-type m2 
and m3 receptors, respectively (Table I). [3H]NMS bind- 
ing activity (KD = 34 + 2 PM) was also found in cells 
co-expressing the chimeric polypeptide combination 
m2-trunc/m3-tail (Table I). Interestingly, cells trans- 
fected with the chimeric m3-trunc/m2-tail construct dis- 
played no specific [3H]NMS binding. Co-transfection of 
m3- trunc/m2-tail plasmid DNA (pcDm3-trunc/m2-tail) 
with an expression plasmid coding for either m2-trunc 
(pcDm2-trunc) or m3-tail (pcDm3-tail) resulted in a ‘re- 
covery’ of muscarinic binding sites (data not shown), 
indicating that pcDm3-trunc/m2-tail n fact directs the 
expression of both encoded polypeptides. 
The ability of the various muscarinic receptor frag- 
ments and fragment combinations to mediate car- 
bachol-induced stimulation of PI hydrolysis was deter- 
mined. Carbachol stimulation of non-transfected COS- 
7 cells or of cells transfected with the various muscarinic 
receptor fragments alone did not result in any detectable 
PI activity. Consistent with their known functional se- 
lectivity [8,9,22], the wild-type m3 receptor mediated a 
pronounced stimulation of PI hydrolysis, whereas the 
m2 receptor was inactive (Table III, Fig. 3). The m3- 
trunc/m3-tail receptor complex stimulated PI hydrolysis 
in a fashion similar to the wild-type m3 receptor (Table 
III, Fig. 3). Like the wild-type m2 receptor, the ‘recon- 
stituted’ m2-trunc/m2-tail and the ‘chimeric’ receptor 
complexes were unable to mediate a significant increase 
in inositol phosphate levels upon carbachol stimulation. 
4. DISCUSSION 
The subtype-selective muscarinic antagonist, 4- 
DAMP, bound to the m2-trunc/m2-tail and m3-trunc/ 
m3-tail receptor complexes with affinities that were not 
significantly different from those found for the wild- 
type m2 and m3 receptors, respectively (Table I). The 
chimeric m2-trunc/m3-tail receptor complex bound 4- 
DAMP with a K, value that was intermediate between 
those determined for the two wild-type receptors (Table I). 
3.2. Agonist binding studies 
We have shown that expression of m2 or m3 muscar- 
inic receptors as two separate polypeptides (one con- 
taining TM I-V, and the other, TM VI and VII; see Fig. 
1) results in the ‘reconstitution’ of functional receptor 
complexes. The reconstituted receptors displayed li- 
gand-binding properties similar to those of the two 
wild-type receptors. These data suggest that the two 
parts of the muscarinic receptors that are covalently 
linked by the i3 loop in the native receptors have the 
capability to fold independently of each other, being 
able to adopt a conformation in the lipid bilayer that 
allows them to recognize each other and form a stable 
receptor complex. 
The ‘reconstituted’ m2-trunc/m2-tail and m3-trunc/ Furthermore, functional studies showed that the m3- 
m3-tail receptor complexes exhibited agonist binding trunc/m3-tail receptor complex mediated a stimulation 
properties similar to those obtained for the wild-type of PI hydrolysis in a fashion similar to the wild-type m3 
Receptor (complex) 
Table II 
Agonist binding properties of muscarinic receptor fragments co-expressed in COS-7 cells 
Acetylcholine Carbachol 
IC,, OtM) nH IC,, WM) nH 
m2 (wild-type) 0.87 + 0.17 0.63 + 0.04 2.14 f 0.6 0.49 + 0.06 
m2-trunc/m2-tail 0.31 * 0.10 0.49 2 0.03 0.65 f 0.2 0.49 f 0.02 
m2-trunc/m3-tail 3.62 k 0.32 0.81 k 0.03 22.0 f 1.9 0.77 f 0.03 
m3 (wild-type) 12.3 f 1.3 0.76 + 0.02 59.3 f 8.7 0.71 It 0.03 
m3-trunc/m3-tail 8.3 f 1.9 0.58 f 0.04 47.7 + 4.8 0.81 k 0.05 
I&, values were obtained in competitton bindmg experiments usmg [-‘H]NMS (200 PM) as a radioligand. Hill coefficients (n,) were stgnificantly 
smaller than 1 (P < 0.05). Data are presented as means f S.E.M. of two or three independent experiments, each performed in duplicate. 
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Fig. 3. Stimulation of PI hydrolysis by m2 and m3 muscarinic receptor 
fragments co-expressed in COS-7 cells. The following symbols are 
used: wild-type m2 (A), m2-trunclmZtai1 (of, m2-trunclm3-tail (o), 
wild-type m3 (e), m3-trun~m3-tail (m), and m3-trun~m2-tail (A). 
Transfected COS-7 cells were incubated with increasing concentra- 
tions of carbachol for I h at 37°C. Increases in intracellular IP, levels 
were determined by anion-exchange chromatography as described 
[21]. Responses are expressed as percentage increase of IP, above basal 
levels determined in the absence of carbachol. The basal IP, levels 
observed for the various ‘trunckail’ receptor complexes were not sig- 
nificantly different from those found for the wild-type m2 and m3 
receptors. Data are presented as means k S.E.M. of two or three 
independent experiments. 
receptor. This finding indicates that a covalent connec- 
tion between TM V and VI (i3) is not required for 
efficient G protein activation. Similar to the wild-type 
m2 receptor, carbachol stimulation of the mZtrunc/m2- 
tail receptor complex did not result in a significant PI 
response, indicating that the reconstituted polypeptide 
complexes retained the functional selectivity of the wild- 
type receptor from which they were derived. Further- 
more, the chimeric m2-trunc/m3-tail receptor was also 
unable to mediate stimulation of PI hydrolysis. This 
finding is consistent with the notion that the N-terminal 
portion of the i3 domain (contained in m2-trunc) is the 
primary structural determinant of how efficiently the 
individual muscarinic receptors are coupled to PI hy- 
drolysis [8,9]. 
The chimeric m2-t~n~m3-~il receptor complex was 
characterized by ligand binding affinities that were in- 
termediate between those found for the wild-type m2 
and m3 receptors. This finding is consistent with the 
notion that the C-terminal muscarinic receptor domains 
(including TM VI and VII) contain major structural 
determinants of ligand binding selectivity [21,23]. The 
lack of detectable [3H]NMS binding activity observed 
after transfection with ~Dm3-trunc/m2-tail may be due 
to conformational incompatibilities between the N-ter- 
minal m3 and the C-terminal m2 receptor sequences 
which do not allow the formation of functional receptor 
complexes. 
Our data support and considerably expand previous 
findings obtained with truncated /?Zadrenergic recep- 
tors [24]. In this case, coinjection into Xenopus oocytes 
of mRNAs coding for two fragmented @2-adrenergic 
receptors (‘split’ within the i3 loop) resulted in the ap- 
pearance of specific adrenergic binding sites. However, 
in contrast to our findings with the m3-trunc/m3-tail 
receptor complex, which proved to be functionally 
highly active, the reconstituted /?Zadrenergic receptor 
was found to be severely impaired in its ability to medi- 
ate adenylyl cyclase activation 1241. The reason for this 
discrepancy remains unclear at present, particularly 
since no EC,, or B,,,,, values were given in this earlier 
study. 
Our findings, together with previous mutagenesis 
studies, suggest hat, as a general rule, G protein-cou- 
pled receptors consist of at least two independent fold- 
ing domains (one containing TM I-V, and the other, 
TM V and VI). Interestingly, studies on the microas- 
sembly of the structurally related integral membrane 
protein, bacteriorhodopsin, have shown that bacteri- 
orhodopsin can be functionally reassembled in lipid ves- 
icles starting from various denatured proteolytic frag- 
ments (for a review, see [13]). In addition, two natural 
Table III 
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393 + 28 
291 k 13 
108 t 15 
7Ort 18 
Maximum increase in IP, Carbachol EC,, 
levels above basal (S) 01M) 
7% 5 
132 1 _ 
12+ 11 
141 * 7 6.1 dz 2.5 
107 Lb 12 0.96 + 0.32 
9rt 4 
EC,, values for carbachol-induced increases in IP, levels were determined graphically from plots of log carbachol concentration vs. percentage 
response. B,,, values were determined in [‘H]NMS saturation binding assays. The amount of transfected wild-type m2 and m3 plasmid DNA was 
reduced to 4@100 mm dish to obtain B,,,, values similar to those found for the various ‘trunckail receptor complexes. Basal IP, levels, determined 
in the absence of carbachol, were not significantly different for the wild-type m2 and m3 receptors and the various ‘tailkrunc receptor complexes. 
Data are presented as means + S.E.M. of two or three independent experiments, each performed in duplicate. 
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cases have been described (cytochrome bdsubunit IV 
and nicotinamide nucleotide transhydrogenase) in 
which a single polypeptide in one type of membrane or 
organism appears to be split into two subunits in an- 
other [13]. Taken together, these findings are consistent 
with the idea that integral membrane proteins are com- 
posed of two or more independent folding domains that 
are inserted into the lipid bilayer as independent units 
and then assembled to form a functional transmem- 
brane protein [14]. Based on the high structural homol- 
ogy found among all G protein-coupled receptors, the 
findings described here should be of general importance 
for this entire class of integral membrane proteins. 
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